JP2005516997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516997A5 JP2005516997A5 JP2003565505A JP2003565505A JP2005516997A5 JP 2005516997 A5 JP2005516997 A5 JP 2005516997A5 JP 2003565505 A JP2003565505 A JP 2003565505A JP 2003565505 A JP2003565505 A JP 2003565505A JP 2005516997 A5 JP2005516997 A5 JP 2005516997A5
- Authority
- JP
- Japan
- Prior art keywords
- mgf
- use according
- polypeptide
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108700024394 Exon Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000003680 myocardial damage Effects 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 1
- 101000832103 Homo sapiens Signal transducer and activator of transcription 5A Proteins 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 102000052934 human STAT5A Human genes 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010065307 rat mechano-growth factor Proteins 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202906.4A GB0202906D0 (en) | 2002-02-07 | 2002-02-07 | Prevention of myocardial damage |
| PCT/GB2003/000537 WO2003066082A1 (en) | 2002-02-07 | 2003-02-06 | Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516997A JP2005516997A (ja) | 2005-06-09 |
| JP2005516997A5 true JP2005516997A5 (https=) | 2006-10-19 |
Family
ID=9930632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565505A Pending JP2005516997A (ja) | 2002-02-07 | 2003-02-06 | 心筋損傷の阻止のためのインスリン様増殖因子iスプライス変異体の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050048028A1 (https=) |
| EP (1) | EP1480669B1 (https=) |
| JP (1) | JP2005516997A (https=) |
| AU (1) | AU2003244511A1 (https=) |
| DK (1) | DK1480669T3 (https=) |
| ES (1) | ES2432082T3 (https=) |
| GB (1) | GB0202906D0 (https=) |
| PT (1) | PT1480669E (https=) |
| WO (1) | WO2003066082A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| AU2006224334A1 (en) * | 2005-03-18 | 2006-09-21 | The Board Of Trustees Of The University Of Illinois | Mecano growth factor peptides and their use |
| WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| KR101459789B1 (ko) | 2006-06-09 | 2014-11-07 | 노파르티스 아게 | 안정화된 인슐린-유사 성장 인자 폴리펩티드 |
| WO2009012443A1 (en) * | 2007-07-18 | 2009-01-22 | The Board Of Trustees Of The University Of Illinois | Nanoparticles for the elution of growth factors for recovery and regeneration of organs |
| CN101891812B (zh) * | 2010-07-09 | 2012-10-17 | 山西大学 | 力生长因子多肽及其制备方法和用途 |
| CN103031277B (zh) * | 2011-09-29 | 2015-07-15 | 重庆大学 | 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460147C2 (de) | 1974-12-19 | 1983-05-05 | Ibm Deutschland Gmbh, 7000 Stuttgart | Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4963665A (en) | 1986-01-07 | 1990-10-16 | Washington University | Human preproinsulin-like growth factor I |
| US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| DK0437563T3 (da) | 1989-08-07 | 1995-05-29 | Debio Rech Pharma Sa | Bioligiske aktive lægemiddelpolymerderivater |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| SE9101341D0 (sv) | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | New medicinal use |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| EP0597033B1 (en) | 1991-08-01 | 1997-04-09 | Genentech, Inc. | Igf-1 to improve the neural condition |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| EP0615452A4 (en) | 1991-11-25 | 1995-07-12 | Inst Molecular Biology Inc | MEDICINE SERVING THE PROMOTION OF THE GROWTH OF A NERVE IN MAMMALS. |
| FR2687681B1 (fr) * | 1992-02-20 | 1995-10-13 | Transgene Sa | Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses. |
| US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| AU1178395A (en) | 1993-11-12 | 1995-05-29 | North Shore University Hospital Research Corporation | Method of treating muscular dystrophy |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5650496A (en) * | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
| GB9605124D0 (en) * | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
| US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| DE69939036D1 (de) | 1998-04-28 | 2008-08-14 | Serono Lab | PEG Konjugate von LHRH Analogen |
| GB9926968D0 (en) | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
| GB0011278D0 (en) * | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
| GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| GB0203552D0 (en) | 2002-02-14 | 2002-04-03 | Beaumont Nicholas J | Peptide growth factor |
| WO2006097682A1 (en) | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
-
2002
- 2002-02-07 GB GBGB0202906.4A patent/GB0202906D0/en not_active Ceased
-
2003
- 2003-02-06 JP JP2003565505A patent/JP2005516997A/ja active Pending
- 2003-02-06 EP EP03737378A patent/EP1480669B1/en not_active Expired - Lifetime
- 2003-02-06 AU AU2003244511A patent/AU2003244511A1/en not_active Abandoned
- 2003-02-06 WO PCT/GB2003/000537 patent/WO2003066082A1/en not_active Ceased
- 2003-02-06 DK DK03737378.4T patent/DK1480669T3/da active
- 2003-02-06 ES ES03737378T patent/ES2432082T3/es not_active Expired - Lifetime
- 2003-02-06 PT PT37373784T patent/PT1480669E/pt unknown
- 2003-02-06 US US10/504,078 patent/US20050048028A1/en not_active Abandoned
-
2007
- 2007-03-20 US US11/723,493 patent/US20080039390A1/en not_active Abandoned
-
2012
- 2012-09-21 US US13/624,365 patent/US9919031B2/en not_active Expired - Fee Related
-
2018
- 2018-03-13 US US15/920,361 patent/US20180271942A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010110330A5 (https=) | ||
| JP2005505286A5 (https=) | ||
| US20110059885A1 (en) | Treatment of diseases and conditions mediated by eicosanoids | |
| Graham et al. | Helical antifreeze proteins have independently evolved in fishes on four occasions | |
| JP2020500162A5 (https=) | ||
| JP2006518372A5 (https=) | ||
| JP2004501650A5 (https=) | ||
| EP0425482A1 (en) | HUMAN INSULINALAGE AND PREPARATIONS THEREOF. | |
| JP2010189394A5 (https=) | ||
| JP2021536250A5 (https=) | ||
| JP2012530060A5 (https=) | ||
| JP2011509093A5 (https=) | ||
| JP2005516997A5 (https=) | ||
| JP2020172505A5 (https=) | ||
| JP2019521692A5 (https=) | ||
| US5736363A (en) | IGF-II analogues | |
| PT2393831T (pt) | Omci modificado como inibidor do complemento | |
| JP2008541776A5 (https=) | ||
| Ohno et al. | The grammatical rule for all DNA: junk and coding sequences | |
| WO2002081507A3 (en) | Interferon gamma polypeptide variants | |
| ATE501256T1 (de) | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung | |
| JP2008531463A5 (https=) | ||
| JP2002539829A5 (https=) | ||
| CN101260150A (zh) | 犬钩虫抗凝肽及其制备和应用 | |
| JP2009507474A5 (https=) |